Related references
Note: Only part of the references are listed.IFN-alpha kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study
Frederic A. Houssiau et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience
A. Segarra et al.
LUPUS (2020)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy
Naomi I. Maria et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
Rita Kansal et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease
Robert J. Benschop et al.
MABS (2019)
Sources of Pathogenic Nucleic Acids in Systemic Lupus Erythematosus
Tomas Mustelin et al.
FRONTIERS IN IMMUNOLOGY (2019)
Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases
Maryam Tahvildari et al.
JOURNAL OF IMMUNOLOGY (2019)
The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus
Kun-Lin Lu et al.
CELLS (2019)
IL-12 and IL-23/Th17 axis in systemic lupus erythematosus
Maddalena Larosa et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2019)
Costimulatory pathway targets for autoimmune and inflammatory conditions: clinical successes, failures, and hope for the future
Pamela Spicer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis
Brad H. Rovin et al.
KIDNEY INTERNATIONAL (2019)
PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Joan Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial
Jens Y. Humrich et al.
LANCET RHEUMATOLOGY (2019)
EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL (DZP) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A RANDOMISED, PLACEBO (PBO)-CONTROLLED STUDY
Richard Furie et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Richard A. Furie et al.
LANCET RHEUMATOLOGY (2019)
Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors
Xiaoxue Ma et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Targeting interferons and their pathways in systemic lupus erythematosus
Francois Chasset et al.
AUTOIMMUNITY REVIEWS (2018)
Epratuzumab for the treatment of systemic lupus erythematosus
Daniel Geh et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
Zhi-Wei Lai et al.
LANCET (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study
Joan T. Merrill et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus
Anne B. Satterthwaite
FRONTIERS IN IMMUNOLOGY (2018)
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Joan T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Ronald F. van Vollenhoven et al.
LANCET (2018)
CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
Edward A. Clark et al.
FRONTIERS IN IMMUNOLOGY (2018)
BAFF and BAFF-Receptor in B Cell Selection and Survival
Cristian R. Smulski et al.
FRONTIERS IN IMMUNOLOGY (2018)
Regulation of TLR signaling pathways by microRNAs: implications in inflammatory diseases
Marina Arenas-Padilla et al.
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
Type III Interferons in Viral Infection and Antiviral Immunity
Jian-hua Zhou et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Omics studies: their use in diagnosis and reclassification of SLE and other systemic autoimmune diseases
Maria Teruel et al.
RHEUMATOLOGY (2017)
IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus
Hong Dai et al.
JOURNAL OF IMMUNOLOGY (2017)
IL-17 Signaling: The Yin and the Yang
Nilesh Amatya et al.
TRENDS IN IMMUNOLOGY (2017)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
Megan E. B. Clowse et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-γ Antibody, in Patients With Discoid Lupus Erythematosus
Victoria P. Werth et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation
Chao-Yang Lai et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
Michael J. Boedigheimer et al.
LUPUS SCIENCE & MEDICINE (2017)
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee et al.
DRUGS (2017)
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J. T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)
Kenneth C. Kalunian et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D. A. Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation
Yanwei Wu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2016)
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther Khamashta et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
Romain Banchereau et al.
CELL (2016)
B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6
Shaun W. Jackson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis
Ding Chen et al.
JOURNAL OF IMMUNOLOGY (2016)
Interferon α or β: which is the culprit in autoimmune disease?
Mary K. Crow
NATURE REVIEWS RHEUMATOLOGY (2016)
MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19
Sandra Gallagher et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up
Chi Chiu Mok et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Evidence for genetic association of TBX21 and IFNG with systemic lupus erythematosus in a Chinese Han population
Rui-Xue Leng et al.
SCIENTIFIC REPORTS (2016)
Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models
Xiujin Shen et al.
SCIENTIFIC REPORTS (2016)
Interferon (IFN)-lambda is a potential mediator in lupus nephritis
Agneta Zickert et al.
LUPUS SCIENCE & MEDICINE (2016)
Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial
Zhihong Liu et al.
ANNALS OF INTERNAL MEDICINE (2015)
Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE
Jens Y. Humrich et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
A MULTIPLE DOSE STUDY OF AMG 811 (ANTI-IFN-GAMMA) IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ACTIVE NEPHRITIS
D. A. Martin et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice
Lindsay J. Edwards et al.
CLINICAL IMMUNOLOGY (2015)
The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis
Sahar M. Abdel Galil et al.
CYTOKINE (2015)
Toll-like receptor 8 deletion accelerates autoimmunity in a mouse model of lupus through a Toll-like receptor 7-dependent mechanism
Ngoc Lan Tran et al.
IMMUNOLOGY (2015)
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
Michele W. L. Teng et al.
NATURE MEDICINE (2015)
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
David Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Guanine-Modified Inhibitory Oligonucleotides Efficiently Impair TLR7-and TLR9-Mediated Immune Responses of Human Immune Cells
Franziska Roemmler et al.
PLOS ONE (2015)
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus
William Stohl
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19
Daniel Szili et al.
MABS (2014)
TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice
Benoit Desnues et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Efficacy and Safety of Abatacept in Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2014)
MicroRNA Regulation in Systemic Lupus Erythematosus Pathogenesis
Sheng Yan et al.
Immune Network (2014)
Recent insights into the genetic basis of systemic lupus erythematosus
Ornella Josephine Rullo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
RESULTS OF A RANDOMIZED PLACEBO CONTROLLED PHASE IA STUDY OF AGS-009, A HUMANIZED ANTI-INTERFERON-α MONOCLONAL ANTIBODY IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
I. Tcherepanova et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Disease Mechanisms in RheumatologyTools and Pathways: Plasmacytoid Dendritic Cells and Their Role in Autoimmune Rheumatic Diseases
Maija-Leena Eloranta et al.
ARTHRITIS AND RHEUMATISM (2013)
B-cell-targeted therapies in systemic lupus erythematosus
Vera Sau-Fong Chan et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
Promotion and prevention of autoimmune disease by CD8+T cells
David M. Gravano et al.
JOURNAL OF AUTOIMMUNITY (2013)
Genetic susceptibility to SLE: Recent progress from GWAS
Yong Cui et al.
JOURNAL OF AUTOIMMUNITY (2013)
Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort
Eoghan M. McCarthy et al.
RHEUMATOLOGY (2013)
Treatment with Anti-Interleukin 23 Antibody Ameliorates Disease in Lupus-Prone Mice
Vasileios C. Kyttaris et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice
Chaim O. Jacob et al.
ARTHRITIS AND RHEUMATISM (2012)
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
H. Travis Ichikawa et al.
ARTHRITIS AND RHEUMATISM (2012)
Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE
Matthew M. Seavey et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2012)
Anti-IFN-α/β Receptor Antibody Treatment Ameliorates Disease in Lupus-Predisposed Mice
Roberto Baccala et al.
JOURNAL OF IMMUNOLOGY (2012)
Selective APRIL Blockade Delays Systemic Lupus Erythematosus in Mouse
Bertrand Huard et al.
PLOS ONE (2012)
Functional genetic polymorphisms in interleukin-12B gene in association with systemic lupus erythematosus
Lyuba D. Miteva et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Immunomodulatory functions of type I interferons
Jose M. Gonzalez-Navajas et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Calcium Signaling in Systemic Lupus Erythematosus T Cells A Treatment Target
Vasileios C. Kyttaris et al.
ARTHRITIS AND RHEUMATISM (2011)
Treatment of systemic lupus erythematosus with epratuzumab
Pawel Traczewski et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Greta Guarda et al.
IMMUNITY (2011)
Antibody-Mediated Coengagement of FcγRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus
Holly M. Horton et al.
JOURNAL OF IMMUNOLOGY (2011)
B Cell and BAFF Dependence of IFN-α-Exaggerated Disease in Systemic Lupus Erythematosus-Prone NZM 2328 Mice
Noam Jacob et al.
JOURNAL OF IMMUNOLOGY (2011)
An autoimmune disease prevented by anti-retroviral drugs
Gabriele B. Beck-Engeser et al.
RETROVIROLOGY (2011)
The Efficacy and Safety of Abatacept in Patients With Non-Life-Threatening Manifestations of Systemic Lupus Erythematosus Results of a Twelve-Month, Multicenter, Exploratory, Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial
J. T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus
Cristiana Guiducci et al.
NATURE (2010)
B cells as therapeutic targets in SLE
Inaki Sanz et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus
Jens Y. Humrich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Current Views of Toll-Like Receptor Signaling Pathways
Masahiro Yamamoto et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2010)
Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders
Ana L. Basquiera et al.
HEMATOLOGY (2009)
Critical Role of TLR2 and TLR4 in Autoantibody Production and Glomerulonephritis in lpr Mutation-Induced Mouse Lupus
Aurelia Lartigue et al.
JOURNAL OF IMMUNOLOGY (2009)
The Role of IL-23/IL-17 Axis in Lupus Nephritis
Zheng Zhang et al.
JOURNAL OF IMMUNOLOGY (2009)
Review of recent genome-wide association scans in lupus
R. R. Graham et al.
JOURNAL OF INTERNAL MEDICINE (2009)
Rituximab in systemic lupus erythematosus A systematic review of off-label use in 188 cases
M. Ramos-Casals et al.
LUPUS (2009)
Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus
Dwight H. Kono et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
A. Komatsuda et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
IRAK-4-and MyD88-Dependent Pathways Are Essential for the Removal of Developing Autoreactive B Cells in Humans
Isabelle Isnardi et al.
IMMUNITY (2008)
TLR7-dependent and FcγR-independent production of type I interferon in experimental mouse lupus
Pui Y. Lee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Excessive production of IFN-γ in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B
Masayoshi Harigai et al.
JOURNAL OF IMMUNOLOGY (2008)
Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys
Jose C. Crispin et al.
JOURNAL OF IMMUNOLOGY (2008)
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies
Seung Y. Chu et al.
MOLECULAR IMMUNOLOGY (2008)
A nonsynonymous functional variant in integrin-αM (encoded by ITGAM) is associated with systemic lupus erythematosus
Swapan K. Nath et al.
NATURE GENETICS (2008)
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
Kirsten Neubert et al.
NATURE MEDICINE (2008)
Depletion of B cells in murine lupus: Efficacy and resistance
Anupama Ahuja et al.
JOURNAL OF IMMUNOLOGY (2007)
APRIL polymorphism and systemic lupus erythematosus (SLE) susceptibility
Y. H. Lee et al.
RHEUMATOLOGY (2007)
Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice
Atsushi Sadanaga et al.
ARTHRITIS AND RHEUMATISM (2007)
Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus
Vasileios C. Kyttaris et al.
JOURNAL OF IMMUNOLOGY (2007)
Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration
Tatsuhiro Harada et al.
AUTOIMMUNITY (2007)
Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients
Y. Dai et al.
LUPUS (2007)
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus
Sean R. Christensen et al.
IMMUNITY (2006)
Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus
David Fernandez et al.
ARTHRITIS AND RHEUMATISM (2006)
A Tlr7 translocation accelerates systemic autoimmunity in murine lupus
Srividya Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication
Prapaporn Pisitkun et al.
SCIENCE (2006)
U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7
E Savarese et al.
BLOOD (2006)
Similarities and differences between selective and nonselective BAFF blockade in murine SLE
M Ramanujam et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus
FJ Barrat et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus
TR Hawn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Viral double-stranded RNA aggravates lupus nephritis through toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells
PS Patole et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus
S Sigurdsson et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2005)
A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus
T Koyama et al.
RHEUMATOLOGY (2003)
Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice
ML Santiago-Raber et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
L Bennett et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
EC Baechler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
DT Boumpas et al.
ARTHRITIS AND RHEUMATISM (2003)
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus - Longitudinal observations
W Stohl et al.
ARTHRITIS AND RHEUMATISM (2003)
Serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity
BR Lauwerys et al.
LUPUS (2002)
Cutting edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease
T Higuchi et al.
JOURNAL OF IMMUNOLOGY (2002)
Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice
C Mary et al.
JOURNAL OF IMMUNOLOGY (2000)
IFN-gamma transgenic mice: clues to the pathogenesis of systemic lupus erythematosus?
JP Seery
ARTHRITIS RESEARCH (2000)
Share Paper
